PHARMACEUTICAL COMPOSITION COMPRISING A RYANODINE RECEPTOR ANTAGONIST FOR FACILITATING WOUND HEALING
    7.
    发明公开
    PHARMACEUTICAL COMPOSITION COMPRISING A RYANODINE RECEPTOR ANTAGONIST FOR FACILITATING WOUND HEALING 审中-公开
    WITH A兰尼碱受体拮抗剂促进伤口愈合的药物组合物

    公开(公告)号:EP3079691A2

    公开(公告)日:2016-10-19

    申请号:EP14837102.4

    申请日:2014-12-12

    摘要: The invention relates to the use of pharmaceutical compositions containing as the active agent a compound of formula I in the treatment of dermal wounds. The compositions may be used for the promotion of healing of wounds affecting the deeper layers under the epithelium, including dermal- and sub dermal connective tissue, being cut, punctured, sliced wounds or originating in insufficient tissue perfusion, chronic diseases or other harms. The compositions are formulated for local application and may comprise other active agents contributing to wound healing in addition to a compound of formula (I).

    摘要翻译: 本发明涉及使用我在皮肤创伤的治疗包含作为活性剂式的化合物的药物组合物的。 该组合物可用于促进伤口影响上皮,包括皮肤和子真皮结缔组织,被切割,打孔,切片伤口或起源于组织灌注不足,慢性疾病或其他危害下深层的愈合。 组合物被配制用于局部应用,并且可以包括有助于伤口除了愈合式(I)的化合物的其它活性剂。

    Apparatus and method for producing paver block having mottled tread surface
    8.
    发明公开
    Apparatus and method for producing paver block having mottled tread surface 审中-公开
    的设备和方法生产的铺路元件的具有结构化表面

    公开(公告)号:EP2910354A1

    公开(公告)日:2015-08-26

    申请号:EP14169034.7

    申请日:2014-05-20

    申请人: Barabas, Arpad

    发明人: Barabas, Arpad

    IPC分类号: B28B13/02

    摘要: This invention relates to a method and apparatus for producing paving blocks (K) having ornamented surface, and the apparatus consiss of a starting table (1), and a filling carriage (2) movable along a guide rail (3) towards and above a forming mould (4) comprising at least one mould cavity (4a) and connected to the starting table (1) is arranged; and in an interior space of the filling carriage (2) a first chamber for receiving base material (6a) and at least one second chamber (6b) for receiving ornamenting material are formed and separated by a septum (v), and a feeding device (7) for dispensing a mixture of ornamenting material is arranged in said second chamber (6b), characterized in that the feeding device (7) is formed by a metering plate (9,91,92,93) provided with holes (9a) and a metering member (10,101,102,103) fitted to and movable along the metering plate (9,91,92,93), and further provided by an actuator for moving the metering member (10,101,102,103).

    摘要翻译: 本发明涉及一种方法和装置用于制造铺路块(K)具有饰表面,和一个起始表格(1)的装置consiss,以及填充滑架(2)沿导轨向着和上方的(3)可动 成形模具(4),包括至少一个模腔(4a)和连接到所述起始表(1)布置; 和在填充滑架(2),用于通过一隔膜(v)的接收基体(6a)和至少一个第二腔室(6B),用于接收ornamenting材料形成并分隔开的第一腔室,和一个进给装置的内部空间 (7)用于分配ornamenting材料的混合物被布置在所述第二腔室(6B),在DASS特点模具供给装置(7)是通过提供具有孔的计量板(9,91,92,93)所形成(9a)的 并装配到并沿着计量板(9,91,92,93)移动,并且此外,通过在致动器用于移动该计量部件(10101102103)提供的计量部件(10101102103)。

    VESICULAR STOMATITIS VIRUS FOR PRIME BOOST VACCINES
    10.
    发明公开
    VESICULAR STOMATITIS VIRUS FOR PRIME BOOST VACCINES 有权
    VESIKEL-STOMATITIS VIRUSFÜRPRIME-BOOST-IMPFSTOFFE

    公开(公告)号:EP2794637A1

    公开(公告)日:2014-10-29

    申请号:EP12859997.4

    申请日:2012-12-21

    摘要: The present invention relates to vesicular stomatitis virus (VSV) matrix (M) protein mutants. One mutant M protein includes a glycine changed to a glutamic acid at position (21), a leucine changed to a phenylalanine at position (111) and a methionine changed to an arginine at position (51). Another M protein mutant includes a glycine changed to a glutamic acid at position (22) and a methionine changed to an arginine at positions (48) and (51). Yet another VSV M protein mutant includes a glycine changed to a glutamic acid at position (22), a leucine changed to a phenylalanine at position (110) and a methionine changed to an arginine at positions (48) and (51). The present invention is directed also to recombinant VSVs (rVSV) having these M mutants and to vaccines based on the rVSV having the M mutants of the present invention. These new rVSVs having the mutant M were significantly attenuated and lost virulence, including neurovirulence, and are capable of inducing an immune responses against an antigen of interest. In addition, a rVSV serotype Indiana having the first described M mutant is capable of efficient replication at 31°C, and of poor replication or incapable of replication at about 37°C or higher.

    摘要翻译: 本发明涉及水泡性口炎病毒(VSV)基质(M)蛋白突变体。 一个突变体M蛋白包括在21位改变为谷氨酸的甘氨酸,在111位将亮氨酸变为苯丙氨酸,将甲硫氨酸改变为位置51处的精氨酸。另一种M蛋白突变体包括在位置处变为谷氨酸的甘氨酸 22和甲硫氨酸在位置48和51处改变为精氨酸。另一种VSV M蛋白突变体包括在22位改变为谷氨酸的甘氨酸,将位置110处的亮氨酸变为苯丙氨酸,将位置上的甲硫氨酸变为精氨酸 本发明还涉及具有这些M突变体的重组VSV(rVSV)和基于具有本发明的M突变体的rVSV的疫苗。 具有突变体M的这些新的rVSV被显着减弱并丧失毒力,包括神经毒力,并且能够诱导针对感兴趣的抗原的免疫应答。 此外,具有第一个描述的M突变体的rVSV血清型印第安纳能够在31℃下有效复制,并且在约37℃或更高时能够复制性差或不能复制。